# Extra-perigastric Extranodal Metastasis is a Significant Prognostic Factor in Node-Positive Gastric Cancer

Akiko Tonouchi[1,3] · Masato Sugano[2,4] · Masanori Tokunaga[1] · Shizuki Sugita[1] ·
Masahiro Watanabe[1] · Reo Sato[1] · Akio Kaito[1] · Tetsuo Akimoto[3,5] · Atsushi Ochiai[2,4] ·
Takahiro Kinoshita[1,4] · Takeshi Kuwata[2,4]

## Abstract

*Background* Extranodal metastasis is an isolated tumor nodule without a residual lymph node structure and has been reported as a poor prognostic factor in gastric cancer. The aim of this study is to assess the prognostic value of extranodal metastasis, especially from the viewpoint of its anatomical distribution.

*Methods* A total of 139 consecutive gastric cancer patients who underwent curative surgery with lymph node metastasis between 2008 and 2009 were included. Clinicopathological features and patient survival outcomes were retrospectively assessed. Patients with extranodal metastasis were subdivided into two groups: perigastric extranodal metastasis, located near the perigastric area (#1–#7 according to the Japanese classification of gastric carcinoma 15th edition), and extra-perigastric extranodal metastasis, located alongside the major vessels (#8–#12).

*Results* Extranodal metastasis was found in 51 patients (37%), and it was more frequent in those with bulky, $\geq$pT3, and pStage III tumors. All patients with extra-perigastric extranodal metastasis had recurrence, resulting in a 0% 5-year overall survival rate, which was significantly worse than that of patients with perigastric extranodal metastasis (59%), or those without extranodal metastasis (84%; $P < 0.001$). Multivariable analysis identified the presence of extra-perigastric extranodal metastasis as an independent poor prognostic factor.

*Conclusions* Extranodal metastasis, especially extra-perigastric extranodal metastasis, was a pivotal poor prognostic factor in node-positive gastric cancer. Recognizing extra-perigastric extranodal metastasis would help provide optimal therapeutic options to these high-risk patients.

## Introduction

Gastric cancer is one of the most common cancers in Eastern countries, including Japan, and is one of the leading causes of cancer-related death worldwide [1]. The

✉ Takeshi Kuwata
tkuwata@east.ncc.go.jp

1 Department of Gastric Surgery, National Cancer Center Hospital East, Kashiwa, Japan

2 Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan

3 Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan

4 Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan

5 Department of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan

tumor node metastasis (TNM) classification system, developed by the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC), is the most widely accepted system to predict the prognosis of gastric cancer and plays an important role in selecting the optimal treatment strategy [2–4]. However, risk stratification is still needed to precisely predict gastric cancer patient outcomes to provide more appropriate clinical management.

Extranodal metastasis (ENM) is a histological term that indicates the presence of an isolated tumor nodule without a residual lymph node structure and was first recognized by W.B. Gabriel et al. in 1935. The clinical significance of ENM had been controversial; however, this "tumor deposit," a synonym of ENM, was recognized to be a significant predictor of a worse prognosis for colorectal cancer and is now included in the TNM staging system [4–6].

In the TNM classification criteria for gastric cancer, extranodal metastasis is described as the presence of tumor nodules in the perigastric fat adjacent to a gastric carcinoma, without any evidence of identifiable lymph node tissue, or vascular or neural structures. Although there have been several reports suggesting that the presence of ENM is an independent predictor of poor prognosis in gastric cancer [7–12], no consensus on ENM management in clinical practice has been reached. Additionally, it remains unclear whether all ENMs have the same clinical impact because ENM can be a result of heterogeneous malignant biological behaviors of gastric cancer, such as the extramural spread of a primary tumor and peritoneal metastasis.

The aim of this study was to assess the prognostic value of ENM, especially from the viewpoint of its anatomical distribution. Here, we report the results of our extensive review of the clinicopathological features of node-positive gastric cancer with ENM using a simple definition.

## Patients and methods

### Patients

A total of 452 patients underwent curative gastrectomy for gastric cancer between January 2008 and December 2009 at the National Cancer Center Hospital East. Of these, 139 patients had pathologically positive lymph nodes and were included in this study. Patients with carcinoma in the gastric stump, those with another malignancy, and those with a previous history of chemotherapy were excluded. All clinicopathological data were reviewed retrospectively and analyzed based on the 7th AJCC TNM classification of malignant tumors. The follow-up duration was defined as the time between the operation and the time of the patient's last outpatient clinic visit or death. During the study period, adjuvant chemotherapy with S-1 was administered to patients with pathological stage II/III tumors. This study complied with the standards of the Declaration of Helsinki and current ethical guidelines, and it was approved by the institutional ethics board. The requirement of written informed consent for participation was waived, because this study did not report the findings of a clinical trial, and the study was retrospective in nature, with data analyzed anonymously.

### Pathological examination of ENM and the definition of extra-perigastric ENM

All surgically resected gastric carcinoma specimens from each patient were fixed in formalin and macroscopically examined in detail. The tumors were cut at a thickness of 5 mm, embedded in paraffin, and thinly sliced at 4-μm intervals from the paraffin-embedded block. The slices of the primary lesion and one maximum cross section of each lymph node were then stained with hematoxylin and eosin for routine microscopic pathological examination. Each specimen of the primary lesion and retrieved lymph nodes was reviewed by M.S. and A.T. ENM was defined as microscopic depositions of carcinoma observed around the lymphadenectomy specimens and/or perigastric connective tissue without any residual lymph node structures (Fig. 1). The positive/negative status of ENM was recorded, and patients were divided into ENM-positive or ENM-negative groups. In addition, the ENM-positive group was subdivided into two groups based on the anatomical location of ENM according to the Japanese classification of gastric carcinoma (JCGC) 15th edition. ENM located at perigastric area (#1–#7 according to the JCGC 15th edition) was defined as perigastric ENM (P-ENM). That located alongside the major vessels (#8–#12 according to the JCGC 15th edition) was defined as extra-perigastric ENM (EP-ENM). The morphologic pattern of ENM was subclassified into a separate nodular pattern, perivascular pattern, lymphatic and endovascular pattern (suggestive of derivation from lymphovascular invasion), or a perineural pattern, based on a previous study.

### Statistical analysis

All continuous variables are presented as the median (range), and comparisons between groups were performed using the Mann–Whitney $U$ test for continuous and ordinal variables and the Fisher's exact test for categorical variables. The overall survival (OS) rates were calculated from the date of the operation to death from any cause. Cumulative OS curves were estimated using the Kaplan–Meier method, and the survival curves were compared with the

**Fig. 1** Histology of ENMs. Tumor cell aggregate without lymph node structure of **a** differentiated and **b** undifferentiated cancer cells, respectively (×40). Scale bar 1 mm

log-rank test. To assess the potential prognostic factors, both univariate and multivariable analyses for OS were performed using the Cox proportional hazards model. $P$ values <0.05 were considered statistically significant. All statistical analyses were conducted using the JMP Statistics software program version 11 (SAS Institute Inc, Cary, NC).

## Results

### Patients and tumor characteristics

The clinicopathological characteristics of patients with ($n = 51$) and without ($n = 88$) ENM are listed in Table 1. The median number of retrieved lymph nodes and metastatic lymph nodes was 44 (range 15–107) and 4 (range 1–61), respectively. The positive lymph node ratio, which is the ratio of the metastatic lymph node number to the retrieved lymph node number, ranged from 0.01 to 0.77 (median, 0.10). Histological analysis revealed that the proportion of deeper tumor invasion and bulky tumors

**Table 1** Clinicopathological characteristics of patients with and without ENM

| Variables | ENM-positive ($n = 51$) | ENM-negative ($n = 88$) | $P$ value |
|---|---|---|---|
| *Age (years)* | | | 0.57 |
| Median (range) | 65 (36–86) | 68 (39–86) | |
| *Sex* | | | 0.64 |
| Male | 31 | 57 | |
| Female | 20 | 31 | |
| *Tumor size* | | | 0.006 |
| <80 mm | 31 | 72 | |
| ≥80 mm | 20 | 16 | |
| *Macroscopic type* | | | 0.053 |
| Type 0–2 | 18 | 46 | |
| Type 3, 4 | 33 | 42 | |
| *Depth of invasion* | | | <0.001 |
| pT1 | 2 | 19 | |
| pT2 | 3 | 16 | |
| pT3 | 12 | 29 | |
| pT4a/pT4b | 31/3 | 21/3 | |
| *LN metastasis (UICC 7th)* | | | 0.23 |
| pN1 | 7 | 42 | |
| pN2 | 12 | 27 | |
| pN3a | 19 | 17 | |
| pN3b | 13 | 2 | |
| *Histology* | | | 0.52 |
| Differentiated type | 20 | 42 | |
| Undifferentiated type | 27 | 42 | |
| Mucinous type | 4 | 4 | |
| *Location* | | | 0.33 |
| Upper third | 15 | 20 | |
| Middle third | 22 | 31 | |
| Lower third | 13 | 36 | |
| Entire | 1 | 1 | |
| *Lymphatic invasion* | | | 0.40 |
| Absent | 5 | 13 | |
| Present | 46 | 75 | |
| *Venous invasion* | | | 0.15 |
| Absent | 7 | 21 | |
| Present | 44 | 67 | |
| *Lymph node ratio* | | | <0.001 |
| Median (range) | 0.19 (0.03–0.73) | 0.06 (0.01–0.77) | |
| *Morphologic features* | | | |
| Separate nodular pattern | 36 | – | |
| Perivascular pattern | 22 | – | |
| Perineural pattern | 1 | – | |
| Lymphatic pattern | 9 | – | |
| Endovascular pattern | 13 | – | |

>80 mm was significantly higher in the ENM-positive group. The prevalence of pathological N (pN) stage (based on the 7th UICC), lymphatic invasion, and venous invasion did not differ significantly between the two groups.

Of the 51 patients (36.7%) with ENM, 40 patients (28.8%) had P-ENM and 11 patients (8.0%) had EP-ENM; clinicopathological differences between the groups were also assessed (Table 2). No significant differences were noted in tumor size, depth of invasion, or the presence of lymphovascular invasion. In contrast, pN stage and the positive lymph node ratio were significantly higher in the EP-ENM group. The prevalence of the morphologic patterns of ENM was similar between these two groups.

## Survival analysis

The results of survival analysis are shown in Fig. 2. The median follow-up duration was 60 months (range 1–108) for all patients. The 3-year and 5-year overall survival (OS) rates were 54.2% and 45.5%, respectively, in the ENM-positive group and lower than those (91.8% and 84.4%, respectively) in the ENM-negative group ($P < 0.001$) (Fig. 2a).

Survival curves of the ENM-positive group are stratified by the location of ENM (P-ENM or EP-ENM) (Fig. 2b). The 5-year OS was significantly worse in the EP-ENM

**Table 2** Clinicopathological characteristics of patients with P-ENM and EP-ENM

| Variables | P-ENM (n = 40) | EP-ENM (n = 11) | P value |
|---|---|---|---|
| *Tumor size* | | | 0.06 |
| <80 mm | 27 | 4 | |
| ≥80 mm | 13 | 7 | |
| *Macroscopic type* | | | 0.53 |
| Type 0–2 | 15 | 3 | |
| Type 3, 4 | 25 | 8 | |
| *Depth of invasion* | | | 0.22 |
| pT1 | 2 | 0 | |
| pT2 | 3 | 0 | |
| pT3 | 9 | 3 | |
| pT4a/pT4b | 24/2 | 7/1 | |
| *LN metastasis (UICC 7th)* | | | 0.029 |
| pN1 | 7 | 0 | |
| pN2 | 11 | 1 | |
| pN3a/3b | 16/6 | 3/7 | |
| *Histology* | | | 0.062 |
| Differentiated type | 19 | 1 | |
| Undifferentiated type | 18 | 8 | |
| Mucinous type | 3 | 2 | |
| *Lymphatic invasion* | | | 0.22 |
| Absent | 5 | 0 | |
| Present | 35 | 11 | |
| *Venous invasion* | | | 0.61 |
| Absent | 6 | 1 | |
| Present | 34 | 10 | |
| *Lymph node ratio* | | | 0.018 |
| Median (range) | 0.15 (0.03–0.54) | 0.31 (0.11–0.73) | |
| *Morphologic features* | | | 0.65 |
| Separate nodular pattern | 26 | 10 | |
| Perivascular pattern | 14 | 8 | |
| Perineural pattern | 1 | 0 | |
| Lymphatic pattern | 8 | 1 | |
| Endovascular pattern | 9 | 4 | |
| *Number of ENM* | | | 0.008 |
| Single | 17 | 0 | |
| Multiple | 23 | 11 | |



**Fig. 2** Kaplan–Meier estimates of overall survival after curative gastrectomy in patients **a** with ENM versus without ENM and **b** with perigastric ENM versus with extra-perigastric ENM ($P < 0.001$, log-rank test)

group (0%) than in the P-ENM group (59%) and ENM-negative group (84%).

Postoperative recurrence rate was also significantly higher in the P-ENM group (45%) and EP-ENM group (100%) than in the ENM-negative group (16%). The site of recurrence did not differ among the groups (Electronic supplementary material 1).

### Prognostic factors in univariate and multivariable analysis

The results of univariate and multivariable analyses for OS with all patients ($n = 139$) are shown in Table 3a. The univariate analyses revealed that advanced pathological T stage, N stage, bulky tumors, and the presence of ENM were predictors of poor prognosis. Multivariable analyses revealed that ENM (HR, 3.71; 95% CI 1.89–7.67;

$P = 0.0002$) was independently associated with OS. For the ENM-positive patients ($n = 51$), multivariable analysis demonstrated that EP-ENM (HR, 5.98; 95% CI, 2.71–15.7; $P < 0.0001$) was independently associated with poorer OS (Table 3b).

## Discussion

In this study, we not only confirmed that the presence of ENM is a poor prognostic factor in our node-positive gastric cancer cohort, but also revealed that the presence of ENM beyond the perigastric region, a condition we have named extra-perigastric ENM (EP-ENM), is an independent and significant risk factor for poor clinical outcome.

ENM is reportedly related to positive surgical margin or lymph node metastasis in patients with colorectal cancer,

**Table 3** Cox regression analysis of prognostic factors for overall survival in all patients [$n = 139$, (a)] and in ENM-positive patients [$n = 51$; (b)]

| Parameters | Univariate analysis | | Multivariate analysis | |
| --- | --- | --- | --- | --- |
| | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
| *(a)* | | | | |
| Age (years) | | | | |
| ≥65 versus <65 | 0.82 (0.45–1.53) | 0.54 | | |
| Sex | | | | |
| Male versus female | 1.15 (0.62–2.26) | 0.66 | | |
| Tumor size | | | | |
| ≥80 mm versus <80 mm | **2.35 (1.26–4.31)** | **0.008** | 1.39 (0.72–2.26) | 0.33 |
| Macroscopic type | | | | |
| Type 3, 4 versus Type 0–2 | 1.30 (0.70–2.44) | 0.41 | | |
| pT stage | | | | |
| T4 versus T1-3 | **2.57 (1.39–4.84)** | **0.024** | 1.28 (0.66–2.55) | 0.47 |
| pN stage (UICC 7th) | | | | |
| N2-3 versus N1 | **4.08 (1.85–10.8)** | **<0.01** | 2.18 (0.92–6.03) | 0.078 |
| ENM-positive versus ENM-negative | **5.06 (2.71–9.92)** | **<0.01** | **3.71 (1.89–7.67)** | **0.0002** |
| *(b)* | | | | |
| Age (years) | | | | |
| ≥ 5 versus <65 | 1.05 (0.49–2.22) | 0.90 | | |
| Sex | | | | |
| Male versus female | 1.08 (0.51–2.44) | 0.84 | | |
| Tumor size | | | | |
| ≥ 80 mm versus <80 mm | 1.43 (0.67–3.01) | 0.35 | | |
| Macroscopic type | | | | |
| Type 3, 4 versus Type 0–2 | 1.30 (0.70–2.44) | 0.57 | | |
| pT stage | | | | |
| T4 versus T1-3 | 1.47 (0.67–3.56) | 0.34 | 1.47 (0.67–3.55) | 0.35 |
| pN stage (UICC 7th) | | | | |
| N2-3 versus N1 | 1.10 (0.43–3.76) | 0.85 | 1.08 (0.41–3.69) | 0.88 |
| EP-ENM versus P-ENM | **6.01 (2.58–13.6)** | **<0.01** | **5.98 (2.71–15.7)** | **<0.0001** |

Bold values indicate statistical significance ($P < 0.05$)

contributing to poor survival outcomes [5, 6]. Poor survival outcomes following gastrectomy in patients with ENM have also been reported [7–13], but the contributing factors might be different from those for colorectal cancer. ENM in gastric cancer may include peritoneal metastasis, which may be one reason that the presence of ENM leads to poor prognosis [8].

Gastric cancer with EP-ENM had a critical negative impact on OS, compared to that with P-ENM. Initially, we thought that the etiology might differ between EP- and P-ENM and considered that EP-ENMs were peritoneal metastases. However, unexpectedly, the incidence of peritoneal recurrence did not differ (Electronic supplementary material 1), and the results of histological analysis of the morphologic pattern were similar, between the EP-ENM and P-ENM groups (Table 2), indicating a low possibility that EP-ENM was associated with peritoneal metastasis. However, there was a significant correlation between the presence of EP-ENM and higher pN stage (UICC 7th); therefore, the presence of EP-ENM may reflect the aggressive lymphatic tumor spread.

Our new finding with regard to EP-ENM is important as it clearly demonstrates the insidious heterogeneity of the risk of ENM. Previously, Etoh et al. stratified patients with ENM according to the number of ENM and demonstrated that it affects survival outcomes. In our study, survival outcome was also worse in patients with multiple ENM (5y OS; 33.5%) than in those with single ENM (5y OS, 68.8%; $P = 0.0128$) (Electronic supplementary material 2). However, the number of ENM was affected by the number of retrieved lymph nodes. In addition, ENM sometimes infiltrates into adjacent fat tissue and could merge with another ENM, which makes it difficult to count the number exactly. Therefore, we focused on the location of ENM rather than the number of ENM, and the anatomical location of ENM was adopted for the risk stratification model. This approach revealed that EP-ENM affects survival outcomes to a greater degree than P-ENM. Moreover, we should also emphasize that the recognition of this critical prognostic factor requires no additional processes beyond routine microscopic examination.

In our multivariable analyses, pT stage and pN stages that are generally common prognostic factors were not revealed as the independent poor prognostic factors. In this limited patient group with positive lymph node metastases, this would imply that the presence of ENM has greater impact on the poor prognosis than pT or pN stage. Similarly, in the ENM-positive patient group, pT or pN stage was not found to be the prognostic indicator, especially compared to the EP-ENM group. Taking into consideration that the 5-year OS was 0%, the presence of ENM, especially EP-ENM, would be useful for identifying patients with quite unfavorable prognosis.

Gastrectomy followed by adjuvant chemotherapy has been a standard treatment for locally advanced gastric cancer in Japan, and therefore, postoperative risk stratification based on pathological diagnosis is indispensable to enable the selection of optimal treatment strategies [13–17]. As we have demonstrated here, the prognosis of patients with EP-ENM, regardless of their pathological state, was identical to that of those with N3b or even close to that those with of M1 disease [18]. Therefore, EP-ENM could be integrated into future TNM classification systems, and patients with EP-ENM should be classified to have N3b irrespective of actual number of positive lymph nodes. The novel prognostic factor reported here can help stratify the currently underestimated risk of these patients and can contribute to improving their outcomes by providing appropriate multidisciplinary therapeutic options that address their high-risk levels.

There are several limitations to this study. First, these data were retrospectively analyzed in a single institution, and the number of the targeted patients was relatively small. The result of this study should be validated in the future, preferably via a multicenter prospective study. Second, the definition of ENM has not been precisely determined with regard to various morphologic patterns; therefore, the definition used for the present study included all morphologic types of ENM. However, simple definitions could avoid interobserver difference among pathologists, and we therefore believe this can lead to high reproducibility.

In conclusion, we have confirmed ENM to be a poor prognostic factor in node-positive gastric cancer and have identified a subpopulation of ENM, EP-ENM, which is associated with critically worse clinical outcomes. To the best of our knowledge, this is the first study to have successfully demonstrate that the location of ENM has a strong effect on prognosis. As EP-ENM is easily recognized in routine pathological practice, we hope these findings will be widely used to stratify the risk of the patients and consequently improve the prognosis of these highly advanced diseases.

**Compliance with Ethical Standards**

**Conflict of interest** The authors declare that there is no conflict of interest.

**Human Rights Statement** This study complied with the standards of the Declaration of Helsinki and current ethical guidelines and was approved by the institutional ethics board.

**Informed Consent** Written informed consent for participation in this study was not obtained from the patients, because this study did not

report on a clinical trial and the data were retrospective in nature and analyzed anonymously.

## References

1. Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386
2. Adachi Y, Kamakura T, Mori M et al (1994) Prognostic significance of the number of positive lymph nodes in gastric carcinoma. Br J Surg 81:414–416
3. Nashimoto A, Akazawa K, Isobe Y et al (2013) Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 16:1–27
4. Sobin LH, Gospodarowicz MK, Wittekind C (2009) Classification of malignant tumours, 7th edn. UICC, Geneva
5. Puppa G, Maisonneuve P, Sonzogni A et al (2007) Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. Mod Pathol 20:843–855
6. Ueno H, Mochizuki H, Hashiguchi Y et al (2007) Extramural cancer deposits without nodal structure in colorectal cancer: optimal categorization for prognostic staging. Am J Clin Pathol 127:287–294
7. Ersen A, Unlu MS, Akman T et al (2014) Tumor deposits in gastric carcinomas. Pathol Res Pract 210:565–570
8. Etoh T, Sasako M, Ishikawa K et al (2006) Extranodal metastasis is an indicator of poor prognosis in patients with gastric carcinoma. Br J Surg 93:369–373
9. Lee HS, Lee HE, Yang HK et al (2013) Perigastric tumor deposits in primary gastric cancer: implications for patient prognosis and staging. Ann Surg Oncol 20:1604–1613
10. Nakamura K, Ogoshi K, Makuuchi H (2010) Subclassification of extranodal involvement in gastric cancer patients. Hepatogastroenterology 57:968–974
11. Sun Z, Wang ZN, Xu YY et al (2012) Prognostic significance of tumor deposits in gastric cancer patients who underwent radical surgery. 151:871–881
12. Chen XL, Zhao LY, Xue L et al (2016) Prognostic significance and the role in TNM stage of extranodal metastasis within regional lymph nodes station in gastric carcinoma. Oncotarget 7:67047–67060
13. Bang Y-J, Kim Y-W, Yang H-K et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. The Lancet 379:315–321
14. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820
15. Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393
16. Takahari D, Hamaguchi T, Yoshimura K et al (2014) Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. Gastric Cancer 17:383–386
17. Yoon S, Yoo C, Ryu MH et al (2017) Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer. Gastric Cancer 20:182–189
18. He X, Wu W, Lin Z, et al (2018). Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis. Gastric Cancer 21:391–400